Novartis Sites New Vaccines Headquarters Outside Boston
Pharmaceuticals giant Novartis (Basel, Switzerland, www.novartis.com) has chosen Cambridge, MA, as the global headquarters for its vaccines and diagnostics division.
Pharmaceuticals giant Novartis (Basel, Switzerland, www.novartis.com) has chosen Cambridge, MA, as the global headquarters for its vaccines and diagnostics division. The site is planned to be fully staffed by the second half of 2007 and will be located near the Cambridge-based Novartis Institutes for BioMedical Research, the company’s global pharmaceuticals research headquarters.
The new Novartis Vaccines and Diagnostics site will have approximately 250 employees in positions such as research, development, marketing, human resources, IT, finance, and general management. The majority of the division's leadership team also will be based in Cambridge.
As part of a restructuring of its vaccines business, Novartis is attempting to create a global network of vaccine manufacturing sites and implementing programs to improve reliability and increase supply of influence vaccines. The second-largest supplier of flu vaccines in the US, Novartis expects to complete shipments of more than 30 million influenza vaccines for the current seasonal flu period in the US.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
